v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jul. 31, 2023
Oct. 31, 2022
Current assets:    
Cash and cash equivalents $ 3,198 $ 12,360
Short-term investments 22,336 17,327
Receivables 334 47
Prepaid expenses and other current assets 532 466
Total current assets 26,400 30,200
Operating lease right-of-use asset 178 212
Total assets 26,578 30,412
Current liabilities:    
Accounts payable 94 265
Accrued expenses 1,712 1,726
Operating lease liability 51 46
Total current liabilities 1,857 2,037
Operating lease liability, non-current 136 175
Total liabilities 1,993 2,212
Commitments and contingencies (Note 10)
Shareholders’ equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,017,770 and 30,913,902 shares issued and outstanding as of July 31, 2023 and October 31, 2022, respectively 310 309
Additional paid-in capital 250,716 247,123
Accumulated deficit (225,506) (218,385)
Total shareholders’ equity 25,520 29,047
Noncontrolling interest (Note 2) (935) (847)
Total equity 24,585 28,200
Total liabilities and equity 26,578 30,412
Series A Convertible Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Income Statement [Abstract]        
Revenue $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161
Research and development expenses (including non-cash share-based compensation expenses of $520, $771, $1,517 and $3,014, respectively) 1,088 1,445 3,154 5,018
General and administrative expenses (including non-cash share-based compensation expenses of $697, $675, $1,990 and $2,531, respectively) 1,756 1,352 4,855 5,248
Total operating costs and expenses 2,844 2,797 8,170 10,266
Loss from operations (2,844) (2,797) (7,960) (10,266)
Interest income 296 22 751 24
Net loss (2,548) (2,775) (7,209) (10,242)
Less: Net loss attributable to noncontrolling interest (37) (29) (88) (123)
Net loss attributable to common shareholders $ (2,511) $ (2,746) $ (7,121) $ (10,119)
Net loss per common share attributable to common shareholders:        
Basic $ (0.08) $ (0.09) $ (0.23) $ (0.33)
Diluted $ (0.08) $ (0.09) $ (0.23) $ (0.33)
Weighted average common shares outstanding:        
Basic 30,974 30,451 30,941 30,244
Diluted 30,974 30,451 30,941 30,244

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (7,209) $ (10,242)
Stock option compensation to employees and directors 3,265 4,928
Stock options and warrants issued to consultants 175 546
Common stock issued to consultants 67 72
Amortization of operating lease right-of-use asset 34 31
Change in operating assets and liabilities:    
Receivables (288)
Prepaid expenses and other current assets (65) (400)
Accounts payable (171) 91
Accrued expenses (14) 103
Operating lease liability (34) (28)
Net cash used in operating activities (4,240) (4,899)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (27,502) (11,159)
Proceeds from maturities of short-term investments 22,493 10,348
Net cash used in investing activities (5,009) (811)
Cash flows from financing activities:    
Proceeds from sale of common stock pursuant to employee stock purchase plan 6 6
Proceeds from exercise of stock options 81 830
Net cash provided by financing activities 87 836
Net decrease in cash and cash equivalents (9,162) (4,874)
Cash and cash equivalents at beginning of period 12,360 29,128
Cash and cash equivalents at end of period $ 3,198 $ 24,254

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL